A new joint guideline published today from the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America, increases the focus on preventing heart failure (HF) in people who are showing early signs of "pre-heart failure," and updates treatment strategies for people with symptomatic heart failure to include SGLT-2 inhibitor (SGLT2i) medicines. The guideline also offers recommendations for managing cardiac amyloidosis, cardio-oncology complications, comorbidities in the setting of heart failure, as well as consideration for implantable devices and advanced therapies for people with stage D heart failure.

Heart failure is a chronic condition that is usually manageable with medication and lifestyle changes. The most common causes of heart failure include narrowed heart arteries, heart attack, high blood pressure and valvular heart disease. Other causes can include, but are not limited to, familial or genetic cardiomyopathies, amyloidosis, metabolic disease, autoimmune disorders or exposure to cardiotoxic agents, such as chemotherapy or other medications. Primary prevention is important for those at risk of HF or pre-HF.

"One primary goal with the new guideline was to use recently published data to update our recommendations for the evaluation and management of heart failure," said Paul A. Heidenreich, MD, MS, guideline writing committee chair. "One focus was prevention of heart failure through optimizing blood pressure control and adherence to a healthy lifestyle."

The ACC/AHA stages of heart failure, from A—D, emphasize the development and progression of the disease, with advanced stages indicating more serious disease and reduced survival rate. The new guideline revised these stages to identify HF risk factors early, which is stage A, at risk for HF, and to provide treatment before structural changes or signs of decreased heart function occur, which is stage B, pre-HF. The stages are:

- **Stage A**: At Risk for HF. At risk but without symptoms, structural heart disease or blood tests indicating heart muscle injury. This includes people with high blood pressure, diabetes, metabolic syndrome and obesity, exposure to medications or treatments that may damage the heart (i.e., chemotherapy drugs), or hereditary risk for heart failure.

- **Stage B**: Pre-HF. No symptoms or signs of HF, but evidence of one of the following: structural heart disease, such as reduced ejection fraction, enlargement of the heart muscle, abnormalities in heart muscle contraction, or valve disease; increased filling pressures as measured via ultrasound; or risk factors from stage A plus increased levels of B-type natriuretic peptide or persistently elevated cardiac troponin, an indicator of heart muscle injury.

- **Stage C**: Symptomatic HF. Structural heart disease with current or previous symptoms of heart failure. Symptoms include shortness of breath, persistent cough, swelling (in the legs, feet, abdomen), fatigue and nausea.
• Stage D: Advanced HF. HF with symptoms that interfere with daily life, are difficult to control and result in recurrent hospitalizations despite continued guideline-directed medical therapy.

New York Heart Association classification (Class I—IV) is used when people reach symptomatic (stage C) or advanced (stage D) HF, to describe their functional capacity and determine treatment strategies.

With approximately 121.5 million people in the U.S. with high blood pressure, 100 million with obesity, and 28 million with diabetes, a large proportion of the U.S. population can be categorized as stage A and at risk for HF. For people in this category the guideline recommends blood pressure control according to the latest guidelines. A normal resting blood pressure should be below 120/80 mmHg. People with Type 2 diabetes and either established cardiovascular disease or at high cardiovascular risk are recommended to consider SGLT2i medicines, which are shown to improve survival in these populations. In general, the mainstays of cardiovascular disease prevention are recommended to reduce HF risk: healthy lifestyle habits such as physical activity, healthful dietary patterns, avoiding smoking and maintaining a healthy weight.

While stage A (at risk) recommendations are also applicable for those in stage B, people who have pre-HF have an opportunity to incorporate additional medications to prevent symptomatic HF. For people with stage B HF with left ventricle ejection fraction (LVEF) ≤40%, ACE-inhibitors (angiotensin-converting-enzyme inhibitors, or ACEi) should be used to prevent HF symptoms from developing. Angiotensin receptor blockers (ARBs) may be prescribed for individuals with an intolerance or contraindication to ACEi. Both medications help relax the blood vessels and reduce blood pressure. Cholesterol-lowering statins are recommended for people with a history of heart attack or acute coronary syndrome.

People who have progressed to stage C with HF symptoms should receive care from multidisciplinary teams to facilitate guideline-directed medical therapy and self-care support for learning to manage symptoms. Self-care support includes understanding the importance of taking medicine as directed and maintaining healthy behaviors such as restricting sodium intake and staying physically active. They should also understand how to monitor themselves for signs of worsening HF and what to do about these symptoms. Screenings to identify potential medical or social barriers for effective self-care are recommended, as well as education and support to reduce rehospitalization and improve survival. Individuals with stage C HF should be fully vaccinated against respiratory illnesses including COVID-19.

"In recent years, there has been an increase in rigorous science assessing how best to treat symptomatic heart failure. With this new guideline, the writing committee hopes to inform better treatment options for a broader number of our patients with heart failure," Heidenreich said.

Left ventricular ejection fraction (LVEF) informs prognosis and response treatments for people with HF. The left ventricle of the heart is responsible for pumping blood out to the rest of the body. The percentage of blood that is pumped out of the left ventricle is measured as a percentage called ejection fraction. In general, LVEF of ≤50-55% is considered normal.

For individuals with stage C HF, the new guideline refines the current four classifications of HF based on LVEF with new terminology:

• HF with reduced ejection fraction (HFrEF) includes people with LVEF ≤40%.
• HF with improved ejection fraction (HFimpEF) includes individuals with previous LVEF ≤40% and a follow-up measurement of LVEF >40%.
• HF with mildly reduced ejection fraction (HFrEF) includes people with LVEF 41-49% and evidence of increased LV filling pressures.
• HF with preserved ejection fraction (HFpEF) includes individuals with LVEF ≥50% and evidence of increased LV filling pressures.
"After careful evaluation of new evidence, guideline-directed medical therapy now includes four medication classes that include SGLT-2 inhibitors. Irrespective of diabetes status, the DAPA-HF and EMPEROR-HF trials have shown the benefit of treating patients with HFrEF with SGLT-2 inhibitors, showing a 30% reduction in heart failure rehospitalization. This is a major step forward in reducing mortality rates in this vulnerable population," said Blykem Bozkurt, MD, Ph.D., guideline writing committee vice-chair.

Pharmacological treatment for people with HFrEF includes four classes of medications, in addition to diuretics, which are recommended for patients with fluid retention. Use of angiotensin receptor-neprilysin inhibitors (ARNi) is recommended, and if not feasible, the use of ACEi is recommended. ARBs are recommended for individuals with an intolerance or potential adverse reaction to ACEi medicines. Mineralocorticoid receptor antagonists (MRA) or beta blockers are also recommended as in the prior guideline. SGLT2i are now recommended for people with symptomatic chronic HFrEF regardless of the presence of Type 2 diabetes.

Individuals with HFmrEF or those with LVEF 41-49% should be treated first with an SGLT2i along with diuretics as needed. ARNi, ACEi, ARB, MRA and beta blockers are considered weaker recommendations in this population, as the evidence in this population is less robust. As LVEF may change over time, people with HFmrEF should have repeat evaluations of LVEF.

People with HFP EF and hypertension should aim for blood pressure targets in accordance with clinical guidelines. For people with HFP EF, SGLT2i may be beneficial in decreasing HF hospitalization and cardiovascular mortality. Management of atrial fibrillation can also improve symptoms. In select individuals with HFP EF, MRAs, ARBs and ARNi may be considered, particularly among people with LVEF on the lower end of the spectrum of HFP EF.

The guideline also includes recommendations for implantable cardiac devices and cardiac revascularization therapy, diagnosis and treatment of cardiac amyloidosis, specialty referrals for individuals with stage D advanced HF, and recommendations for management of atrial fibrillation and valvular heart disease in HF and cardio-oncology.

This new heart failure guideline replaces the 2013 ACCF/AHA Guideline for the Management of Heart Failure and the 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. The guideline is targeted to all clinicians who are involved in the care of people with cardiovascular disease with or without heart failure.

The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" will publish simultaneously in the Journal of the American College of Cardiology, journal Circulation and the Journal of Cardiac Failure.


Provided by American College of Cardiology